(TheNewswire)
Edmonton, AB - TheNewswire - May 15, 2023 - Innovotech Inc. (TSX-V:IOT) reports that itsInnovoSIL™-1 silver periodate antimicrobial compound acts as anexcellent antimicrobial against Candida auris .
C. auris is an emergingfungus (yeast) causing a serious global health threat due to itsresistance to antibiotic treatments and its tendency to cause severeillness in people with weakened immune systems. C. auris infections have beenassociated with 30-60% mortality rates in hospitalized patients.
Coated onto a wound dressing model, InnovoSIL™-1 silver prevented abroad spectrum of microorganisms from adhering to the dressing surfaceover time under clinically relevant conditions, while eliminatingsurrounding planktonic (free-floating) microorganisms. Otherorganisms tested included superbugs well-known for causingdifficult-to-treat infections that tend to spread rapidly inhealthcare settings: Methicillin-Resistant Staphylococcus aureus (MRSA),Vancomycin-Resistant Enterococcusfaecalis (VRE), Coagulase Negative Staphylococcus epidermidis (CONS),and Acinetobacter baumannii .
The evaluation was performed using Innovotech’s proprietary BESTAssay™ testing system, which is included in its scope ofaccreditation under ISO 17025:2017.
About InnovoSIL™-1 AntimicrobialSilver
InnovoSIL™-1 antimicrobial silver possesses exceptional propertiesfor efficacy against microbial biofilms as well as simplicity forcoating onto or incorporating into medical devices, with favorablerelease characteristics. The unique structure around the silverpresent in the anion slows its inactivation by bodily fluids.Combining silver and iodine increases antimicrobial mechanisms ofaction, reducing the likelihood of a target developing resistance toit. InnovoSIL™-1 antimicrobial silver has demonstrated excellentstability under a wide variety of challenges and can be easilysynthesized with high purity in a form that is simple to deposit ontometals or incorporate into wound dressings, gels, or polymers. Innovotech is presently working with a number of industrycollaborators who are pursuing a variety of applications forInnovoSIL™-1 antimicrobial silver.
About Innovotech
Innovotech is a Canadian biotechnology company owning proprietaryintellectual property, conducting contract research, and owning andproviding proprietary devices for testing in multiple applications inmicrobiology. Innovotech can be found online at www.innovotech.ca .
“Patricia Nadworny”
Dr. Patricia Nadworny, Ph.D, B.Sc, P.Eng
Chief Scientific Officer and Quality & Safety Director
Innovotech Inc.
780-448-0585 ext. 7
patricia.nadworny@innovotech.ca
This document may containforward-looking statements that are predictive in nature and subjectto risks and uncertainties that cannot be predicted or quantified;consequently, actual results may differ materially from past resultsand those expressed or implied by any forward-looking statements.Factors that could cause or contribute to such risks or uncertaintiesinclude, but are not limited to: the regulatory environment includingthe difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; theCompany’s reliance on a small number of customers includinggovernment organizations; fluctuations in operating results;government policies or actions; progress and cost of clinical trials;reliance on key strategic relationships; uncertainty related tointellectual property protection and potential costs associated withits defense; the Company’s exposure to lawsuits and other mattersbeyond the control of management. Should known or unknown risks oruncertainties materialize, or should management’s assumptions proveinaccurate, actual results could vary materially from thoseanticipated. The Company undertakes no obligation to publicly make orupdate any forward-looking statements, except as required byapplicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (asthat term is defined in the policies of the TSX Venture Exchange)accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.